HQL offers a high 12% yield and trades at a discount, making it attractive for income-focused investors seeking healthcare sector exposure. The fund is heavily weighted in biotechnology, leading to ...
abrdn Life Sciences Investors remains a buy for high-yield seekers, offering a 10.1% dividend yield and diversified healthcare exposure. HQL trades at a 7.92% discount to NAV, with its share price ...
PHILADELPHIA, PA / ACCESSWIRE / May 9, 2024 / abrdn Life Sciences Investors (HQL) and abrdn Healthcare Investors (HQH), (collectively, the "Funds") each, a closed-end management investment company, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback